ORGAN-Specific Peptide Canine Safety Study |Biomedgrid

Extending the quality of life of companion pets is humane to pets and is of value to pet owners. Several veterinary life-saving therapeutic technologies have been proposed. We have developed novel peptide therapies for both clinical and companion pets using organ-specific stem cell derived peptides under the name Biopep Inc. Our first peptide therapy, EW-iJMP7, is comprised of signaling peptides that are associated with the maintenance of regular bone, cartilage, joint and synovial fluids and are found in the placenta, central nervous system, and thymus. In this study, we aim to determine the effect of Intramuscular (IM) de-livery of these well characterized peptides in canine models. We gave six adult dogs once weekly injection of the EW-iJMP7 cocktail intramuscularly. These animals were euthanized after 1 or 2 weeks. Blood analysis was conducted to assess whole blood count and chemistry prior to euthanasia. Liver, kidney, heart, and lung samples were collected after euthanasia for histopathology analysis. Our results indicated that EW-iJMP7 injection did not cause observable side effects in dogs' appearance or behavior, however, it resulted in a Significant Reduction Of Platelet Count and ALT (SGPT) which remained within the normal range, and a significant increase of BUN/Creatinine ratio above the normal range. Data from this study will provide safety data on advancing this technology to assist and support further studies in animal models of longevity and arthritis in companion pets.